AstraZeneca PLC (LON:AZN) Buy Rating Reiterated at Deutsche Bank; Shorts at Sanofi (SNY) Lowered By 3.45%

Sanofi (NYSE:SNY) had a decrease of 3.45% in short interest. SNY’s SI was 1.74 million shares in February as released by FINRA. Its down 3.45% from 1.81 million shares previously. With 989,000 avg volume, 2 days are for Sanofi (NYSE:SNY)’s short sellers to cover SNY’s short positions. The SI to Sanofi’s float is 0.08%. The stock decreased 3.86% or $1.67 during the last trading session, reaching $41.55. About 5.31M shares traded or 239.12% up from the average. Sanofi (NYSE:SNY) has risen 26.96% since February 6, 2017 and is uptrending. It has outperformed by 10.26% the S&P500.

In a research note sent to investors on 6 February, AstraZeneca PLC (LON:AZN) stock had its Buy Rating restate by research professionals at Deutsche Bank.

The stock decreased 2.45% or GBX 119.5 during the last trading session, reaching GBX 4767. About 951,444 shares traded. AstraZeneca PLC (LON:AZN) has 0.00% since February 6, 2017 and is . It has underperformed by 16.70% the S&P500.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of 60.36 billion GBP. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 20.11 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

Among 31 analysts covering AstraZeneca PLC (LON:AZN), 18 have Buy rating, 3 Sell and 10 Hold. Therefore 58% are positive. AstraZeneca PLC has GBX 7600 highest and GBX 4.57 lowest target. GBX 5102.08’s average target is 7.03% above currents GBX 4767 stock price. AstraZeneca PLC had 605 analyst reports since July 23, 2015 according to SRatingsIntel. As per Monday, September 11, the company rating was maintained by Goldman Sachs. The company was maintained on Wednesday, April 20 by Jefferies. The rating was maintained by UBS on Monday, September 19 with “Buy”. Deutsche Bank maintained it with “Buy” rating and GBX 5600 target in Thursday, April 7 report. The firm has “Buy” rating by Deutsche Bank given on Thursday, September 8. Cantor Fitzgerald maintained the shares of AZN in report on Friday, October 28 with “Buy” rating. The firm has “Sell” rating given on Thursday, May 11 by Shore Capital. JP Morgan maintained the stock with “Neutral” rating in Wednesday, November 1 report. As per Tuesday, February 2, the company rating was maintained by Handelsbanken. The rating was maintained by Credit Suisse on Monday, February 5 with “Outperform”.